



J. Greg Davis Appointed President & Chief Executive Officer of Tryton Medical, Inc.

FOR IMMEDIATE RELEASE

Research Triangle Park, NC, USA - April 28, 2008 - Tryton Medical, Inc. announced today that it has appointed J. Greg Davis as President and Chief Executive Officer. Founded in 2003, Tryton Medical is the leading developer of stents that are designed to definitively treat bifurcation lesions.

Mr. Davis joins Tryton Medical after a successful 20-year career with Guidant and Eli Lilly & Company. Mr. Davis is an experienced medical device executive with broad global and functional experience in finance, manufacturing, sales and general management. Most recently he was president of Guidant, Japan with profit and loss responsibility for the company's \$225 million cardiovascular business. Prior to his work in Japan, Mr. Davis managed Guidant's product portfolio in 13 Asian countries. Mr. Davis earned a BS in Mechanical Engineering from The University of Minnesota and an MBA from The University of Michigan.

"I am excited about this opportunity because I believe the Tryton [Side-Branch Stent™](#) will redefine the standard of care for bifurcation lesions," said Mr. Davis. "Tryton's elegant design, ease-of-use and stellar clinical results are impressive. I look forward to implementing the company's aggressive European commercialization strategy and U.S. clinical trial plans."

"We are delighted to welcome Greg to Tryton Medical during this pivotal time in the company's development," said Dan Cole, Co-Founder and Board Member of Tryton and General Partner of Spray Venture Partners. "We believe his proven track record of growing successful businesses and achieving results will enable Tryton to capitalize on its leadership position in the industry."

"Greg's rich international experience and customer focus will be real assets as we launch the [Side-Branch Stent™](#) across Europe," said Rick Anderson, Board Member of Tryton and Managing Director of PTV Sciences, and former Company Group Chairman, Cordis Corporation. "The Tryton 1 (First in Man) trial results and recent CE Mark approval have created strong interest and enthusiasm among the European physician community."

About Tryton Medical, Inc.

Tryton Medical, Inc. was founded in 2003 by Aaron V. Kaplan, M.D. (Associate Professor of Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The company recently completed a \$14 million round of financing, led by PTV Sciences and RiverVest Venture Partners. The Company will be headquartered in Research Triangle Park, NC. For more information on Tryton Medical contact J. Greg Davis, at gdavis@trytonmedical.com or visit www.trytonmedical.com.

###